Sensipar
Drug
Amgen Inc.
Total Payments
$1.1M
Transactions
2,903
Doctors
1,595
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2022 | $76.34 | 3 | 3 |
| 2021 | $3,367 | 4 | 3 |
| 2020 | $23,923 | 7 | 3 |
| 2019 | $210,238 | 7 | 3 |
| 2018 | $64,951 | 88 | 35 |
| 2017 | $766,632 | 2,794 | 1,572 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $728,628 | 117 | 68.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $211,250 | 148 | 19.8% |
| Food and Beverage | $53,826 | 2,513 | 5.0% |
| Travel and Lodging | $37,616 | 109 | 3.5% |
| Consulting Fee | $34,714 | 11 | 3.2% |
| Space rental or facility fees (teaching hospital only) | $3,100 | 3 | 0.3% |
| Education | $52.91 | 2 | 0.0% |
Payments by Type
Research
$728,628
117 transactions
General
$340,559
2,786 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Comparative Effectiveness and Safety of Cinacalcet (a Nested Case Control Study) | Amgen Inc. | $248,975 | 0 |
| EVOLVE | Amgen Inc. | $206,776 | 1 |
| 356 Rollover Safety Extension | Amgen Inc. | $90,944 | 0 |
| Cinacalcet Open label; single arm study in pediatric dialysis subjects with SHPT | Amgen Inc. | $67,158 | 1 |
| Pediatric 26week; Time until Transplant | Amgen Inc. | $58,536 | 0 |
| Sensipar Pediatric Age 28d6yrs Sdose PK Study | Amgen Inc. | $32,629 | 0 |
| Sensipar -Pediatrics - Safety & Efficacy | Amgen Inc. | $18,233 | 0 |
| Fibroblast Growth Factor 23 as a Risk Factor for Cardiovascular Events and Mortality in Patients in | Amgen Inc. | $4,602 | 1 |
| Impact of Adherence to Tumor Necrosis Factor Inhibitors (TNFi) on Radiographic Outcomes of TNFi Use | Amgen Inc. | $774.60 | 0 |
Top Doctors Receiving Payments for Sensipar — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Nephrology | Torrance, CA | $2,765 | 3 |
| , MD | Nephrology | Columbia, SC | $2,216 | 2 |
| Kotagal Kant | Internal Medicine | Cincinnati, OH | $2,200 | 1 |
| , MD | Pediatric Nephrology | Houston, TX | $1,996 | 2 |
| , D.O | Specialist | Mobile, AL | $1,658 | 5 |
| , MD | Specialist | San Antonio, TX | $1,644 | 4 |
| , M.D | Internal Medicine | Webster, TX | $1,624 | 4 |
| , DO | Nephrology | Eatontown, NJ | $1,616 | 3 |
| , DO | Nephrology | Minneapolis, MN | $1,600 | 2 |
| , M.D | Internal Medicine | San Antonio, TX | $1,600 | 2 |
| , DO | Nephrology | Evanston, IL | $1,600 | 2 |
| , M.D | Nephrology | Pasadena, CA | $1,600 | 2 |
| , M.D | Internal Medicine | Houston, TX | $1,600 | 2 |
| , M.D | Nephrology | Inglewood, CA | $1,465 | 5 |
| , MD | Nephrology | Springfield, MA | $1,026 | 3 |
| , MD | Nephrology | Los Angeles, CA | $869.85 | 3 |
| , MD | Nephrology | Augusta, GA | $811.76 | 2 |
| , MD | Internal Medicine | Pembroke Pines, FL | $800.00 | 1 |
| , MD | Nephrology | Bronx, NY | $800.00 | 1 |
| , MD | Nephrology | Houston, TX | $800.00 | 1 |
| , MD | Nephrology | Philadelphia, PA | $761.10 | 3 |
| , M.D | Nephrology | Calabasas, CA | $182.41 | 4 |
| , M.D | Nephrology | North Syracuse, NY | $181.77 | 13 |
| , MD | Internal Medicine | Henderson, NV | $176.65 | 7 |
| , MD | Nephrology | Albuquerque, NM | $156.66 | 4 |
Ad
Manufacturing Companies
- Amgen Inc. $1.1M
Product Information
- Type Drug
- Total Payments $1.1M
- Total Doctors 1,595
- Transactions 2,903
About Sensipar
Sensipar is a drug associated with $1.1M in payments to 1,595 healthcare providers, recorded across 2,903 transactions in the CMS Open Payments database. The primary manufacturer is Amgen Inc..
Payment data is available from 2017 to 2022. In 2022, $76.34 was paid across 3 transactions to 3 doctors.
The most common payment nature for Sensipar is "Unspecified" ($728,628, 68.1% of total).
Sensipar is associated with 9 research studies, including "Comparative Effectiveness and Safety of Cinacalcet (a Nested Case Control Study)" ($248,975).